Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Monika KellererMargit Staum KaltoftJack LawsonLasse Lykke NielsenKrzysztof StrojekÖmür TabakStephan JacobPublished in: Diabetes, obesity & metabolism (2022)
In this basal insulin-treated population, OW semaglutide improved glycaemic control to a greater extent than TID IAsp and provided numerically greater weight loss.